Trial reportPsychopharmacology2005
The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment.
Trial report in Psychopharmacology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 89 citations in OpenAlex.
- S100B Serum Levels Predict Treatment Response in Patients with Melancholic Depression.The international journal of neuropsychopharmacology · 2015Trial
- Are S100B and VILIP-1 Involved in a Common Mechanism of Neuroinflammation in Major Depressive Disorder?The Psychiatric quarterly · 2025Article
- Peripheral S100B Protein Levels in Five Major Psychiatric Disorders: A Systematic Review.Brain sciences · 2023Review
- Glial-Neuronal Interaction in Synapses: A Possible Mechanism of the Pathophysiology of Bipolar Disorder.Advances in experimental medicine and biology · 2023Review
- High S100B Levels Predict Antidepressant Response in Patients With Major Depression Even When Considering Inflammatory and Metabolic Markers.The international journal of neuropsychopharmacology · 2022Article
- Inflammation-driven brain and gut barrier dysfunction in stress and mood disorders.The European journal of neuroscience · 2022Review
- Predictive Power of Cognitive Biomarkers in Neurodegenerative Disease Drug Development: Utility of the P300 Event-Related Potential.Neural plasticity · 2022Review
- Longitudinal assessment of S100B serum levels and clinical factors in youth patients with mood disorders.Scientific reports · 2021Article
- S100B Levels in Patients with Type 2 Diabetes Mellitus and Co-Occurring Depressive Symptoms.Depression research and treatment · 2018Article
- Emotion Processing by ERP Combined with Development and Plasticity.Neural plasticity · 2017Review
- Venlafaxine ameliorates the depression-like behaviors and hippocampal S100B expression in a rat depression model.Behavioral and brain functions : BBF · 2016Article
- Stem Cell Factor (SCF) is a putative biomarker of antidepressant response.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2016Article
- Serum S100B Protein Levels in Patients with Panic Disorder: Effect of Treatment with Selective Serotonine Reuptake Inhibitors.Psychiatry investigation · 2015Article
- First evidence for glial pathology in late life minor depression: S100B is increased in males with minor depression.Frontiers in cellular neuroscience · 2015Article
- Serum S100B represents a new biomarker for mood disorders.Current drug targets · 2013Review
- Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue.Current drug targets · 2013Review
- Article
- Mood disorders are glial disorders: evidence from in vivo studies.Cardiovascular psychiatry and neurology · 2010Article
- Neuropsychiatric disorders related to interferon and interleukins treatment.Metabolic brain disease · 2009Review
- The effects of gender and numbers of depressive episodes on serum S100B levels in patients with major depression.Journal of neural transmission (Vienna, Austria : 1996) · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleS100B is an astrocytic, calcium-binding protein which in nanomolar concentrations has neuroprotective and regenerating effects on neurons and glial cells. Increased levels have been shown to be positively correlated with therapeutic response in major depression. Event-related potentials (ERP) have been reported to be impaired in depressed patients.
objectivesThe aim of our study was to assess the relationship between S100B and visually evoked ERP in depression.
methodsERP and S100B serum concentration were studied in 18 patients with major depression, before and after 4 weeks of antidepressant treatment.
resultsThe S100B concentration in patients was increased at intake and after 4 weeks of treatment compared to healthy controls. Initially increased P3-latency normalized and P2-latency significantly decreased after 4 weeks of treatment, although only in patients with clearly elevated initial S100B levels (mean plus 2 SD of the healthy controls).
conclusionThe neuroregenerative activity of moderately increased S100B levels in major depression might be a factor contributing to a decrease of prolonged ERP parameters in major depression during antidepressant treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.